- Nitric Oxide Production
- Increased Blood Flow (PUMP)
- Vegan Caps
Glycine Propionyl-L-Carnitine (GPLC/) is a molecularly-bonded combination of propionyl-l-carnitine and the amino acid glycine. Propionyl-l-carnitine is a type of acylcarnitine that has a high affinity for skeletal and cardiac muscles. It has a number of physiological effects, including: 1) a vasodilatory effect, 2) providing a source of propionyl units which can be converted into succinate for use by the mitochondria during the citric acid cycle, and 3) replenishing free carnitine levels during intense exercise or where there is any deficiency. Glycine is believed to be a glucogenic amino acid and therefore may help to regulate blood sugar. It is also required for the formation of creatine and appears to also have a vasodillatory effect. Research has shown that short and long term supplementation with GPLC can significantly enhance anaerobic capacity and reduced lactate production. This is believed to be mainly due to GPLC’s ability to increase Nitric Oxide production, which in turn enhances blood flow to the active muscles. GPLC also has potent antioxidant properties and may protect against lipid peroxidation.
Naturally created from the chemical arginine. Agmatine has been shown to exert modulatory action at multiple molecular targets, notably: neurotransmitter systems, ion channels, nitric oxide (NO) synthesis and polyamine metabolism.
- EDR: A seminal study showed 15% improvement in vasodilation (Fitzpatrick 2000). If we wanted to, we could put a chart up showing a 300% increase over L-Arginine, and it would be true. But, we chose to skip hyperbole and go straight to the science indicating a 15% improvement over placebo! If you think that’s cool, VASO6 contains enough Timer Gallate E3 to produce 50% vasodilation identified in fraction E, peak 3. (US patent 6,706,756 B1)!
- NO production
- Reduced blood platelet aggregation and improved blood lipid profile (Bottino 2014 and Pon 2008)
- Combats endothelial dysfunction (Corder 2004)
- Diminishes vascular smooth muscle cells (VSMC) (Fitzpatrick 2002)